Indaptus Therapeutics Announces Opening Of Next Cohort In Single Dose Ranging Study Of Decoy20
Portfolio Pulse from Happy Mohamed
Indaptus Therapeutics, Inc. (NASDAQ:INDP) has completed the first cohort of patients in its INDP-D101 trial of Decoy20 and initiated a new cohort. The first cohort showed a significant immune response and short-lived symptoms consistent with the mechanism of Decoy20. The company expects the next cohort will help determine the recommended phase 2 dose. The company plans for multi-dosing and combination studies in 2024.
August 10, 2023 | 12:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Indaptus Therapeutics' successful completion of the first cohort in its INDP-D101 trial of Decoy20 and initiation of a new cohort could potentially boost investor confidence in the company's research and development capabilities.
The successful completion of the first cohort in the INDP-D101 trial and the initiation of a new cohort indicates progress in the company's research and development efforts. This could potentially boost investor confidence in the company's ability to develop and bring new products to market, which could have a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100